Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.21.2
Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jan. 01, 2021
Jul. 22, 2016
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
May 24, 2021
Dec. 31, 2020
Dec. 04, 2020
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock, shares authorized     150,000,000   150,000,000     125,000,000    
Common stock par value (in dollars per share)     $ 0.0001   $ 0.0001     $ 0.0001    
Preferred stock, shares authorized     2,000,000   2,000,000     2,000,000    
Aggregate value of shares subscribed     $ 185,000   $ 185,000     $ 7,939,000    
Common stock, shares issued     89,936,162   89,936,162     70,920,693    
Common stock, shares issuable     52,019   52,019     2,103,122    
Proceeds from issuance of common shares         $ 0 $ 37,230,000        
Aggregate fees of stock issuance         $ 0 $ 2,234,000        
Shares available for future sale     803,181   803,181          
Share-based compensation expense under ESPP     $ 29,000 $ 0            
Proceeds from employee stock purchase plan         $ 200,000          
Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Percentage of fully diluted equity 2.50% 2.50%       2.50%        
Expenses from related party transaction         $ 250,000 $ 250,000        
Issuance of common shares (in shares)         452,965 53,390        
Shares issued, price per share     $ 3.50 $ 3.76 $ 3.50 $ 3.76        
Common stock, shares issuable     52,019   52,019          
Proceeds from issuance of common shares           $ 63,800,000        
At the Market Offering [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Agent commission (as a percent)                   3.00%
Issuance of common shares (in shares)         16,200,000 2,100,000        
Shares issued, price per share     $ 3.94 $ 3.76 $ 3.94 $ 3.76        
Proceeds from issuance of common shares         $ 63,800,000 $ 8,000,000.0        
Proceeds from issuance of Common Stock, net of offering costs         62,600,000 7,800,000        
Aggregate fees of stock issuance         1,200,000 $ 200,000        
Registration Statements [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Sale of Stock aggregate offering price permitted by agreement             $ 200,000,000.0   $ 100,000,000.0 $ 75,000,000.0
Common stock shares available for future issuance     $ 22,300,000   $ 22,300,000          
Class A Common Shares [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock, shares issued     845,385   845,385     845,385    
Preferred Class A [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Preferred stock, shares issued     250,000   250,000     250,000    
General and Administrative [Member] | Fortress Biotech, Inc [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Expenses from related party transaction         $ 1,600,000